Work

Abstract P3-09-15: A phase 1b study of PVX-410 (PVX) vaccine plus durvalumab (DUR) as adjuvant therapy in HLA-A2+ early stage triple negative breast cancer (eTNBC) to assess safety and immune response

Year: 2020

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs19-p3-09-15

Authors: Steven J Isakoff, Sylvia Adams, Hatem H Soliman, Nadine Tung, William T Barry, Jiani Hu, Lorenzo Trippa, Rachel Deering, Joanne Parker, Hannah Park, Elena F Brachtel, Leif W Ellisen, Mariano Severgnini, Doris Peterkin, Sara M Tolaney

Institutions: Massachusetts General Hospital, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University, Moffitt Cancer Center, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3010645285

Cites:

Cited by: 11

Related to: 10